Review of estrogen receptor, progesterone receptor, and her-2/neu immunohistochemistry impacts on treatment for a small subset of breast cancer patients transferring care to another institution

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 11, 2013, Pages 1660-1663

  Jorns, Julie M ^a   Healy, Patrick ^b   Zhao, Lili ^b  

^a Departments of Pathology   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; BREAST TUMOR; CONFERENCE PAPER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MALE; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PATIENT REFERRAL; PATIENT TRANSPORT; RETROSPECTIVE STUDY;

ADULT; AGED; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATIENT TRANSFER; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84887831617     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0670-OA     Document Type: Conference Paper

References (19)

1. Chang JH, Vines E, Bertsch H, et al. The impact of a multidisciplinary breast cancer center on recommendations for patient management: The University of Pennsylvania experience. Cancer. 2001;91(7):1231-1237
2. Newman EA, Guest AB, Helvie MA, et al. Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board. Cancer. 2006;107(10):2346-2351
3. Renshaw MA, Renshaw AA, Gould EW. Should pathologists send all or only selected slides for patient-requested interlaboratory second opinion? Am J Clin Pathol. 2009;132(5):763-766
4. Goldman L, Schafer A. Goldman's Cecil Medicine. Vol. 1. 24th ed. St. Louis, MO: WB Saunders (Elsevier); 2011
5. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28(23): 3784-3796
6. Kurian AW, Thompson RN, Gaw AF, et al. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007;25(6):634-641
7. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784-2795
8. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18-43
9. Abt AB, Abt LG, Olt GJ. The effect of interinstitution anatomic pathology consultation on patient care. Arch Pathol Lab Med. 1995;119(6):514-517.
10. Al-Maghrabi JA, Sayadi HH. The importance of second opinion in surgical pathology referral material of lymphoma. Saudi Med J. 2012;33(4):399-405
11. Kronz JD, Westra WH, Epstein JI. Mandatory second opinion surgical pathology at a large referral hospital. Cancer. 1999;86(11):2426-2435
12. Manion E, Cohen MB, Weydert J. Mandatory second opinion in surgical pathology referral material: Clinical consequences of major disagreements. Am J Surg Pathol. 2008;32(5):732-737
13. Price JA, Grunfeld E, Barnes PJ, Rheaume DE, Rayson D. Inter-institutional pathology consultations for breast cancer: impact on clinical oncology therapy recommendations. Curr Oncol. 2010;17(1):25-32
14. Scott CB, Nelson JS, Farnan NC, et al. Central pathology review in clinical trials for patients with malignant glioma: a report of Radiation Therapy Oncology Group 83-02. Cancer. 1995;76(2):307-313
15. Weir MM, Jan E, Colgan TJ. Interinstitutional pathology consultations: A reassessment. Am J Clin Pathol. 2003;120(3):405-412
16. Bajaj J, Morgenstern N, Sugrue C, Wasserman J, Wasserman P. Clinical impact of second opinion in thyroid fine needle aspiration cytology (FNAC): A study of 922 interinstitutional consultations. Diagn Cytopathol. 2012;40(5):422- 429
17. Bruner JM, Inouye L, Fuller GN, Langford LA. Diagnostic discrepancies and their clinical impact in a neuropathology referral practice. Cancer. 1997; 79(4):796-803
18. Epstein JI, Walsh PC, Sanfilippo F. Clinical and cost impact of secondopinion pathology: Review of prostate biopsies prior to radical prostatectomy. Am J Surg Pathol. 1996;20(7):851-857
19. Hung T, Wolber R, Garratt J, Kalloger S, Gilks CB. Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program. Pathology. 2010;42(7):637-642